Autor: |
Tarisawa M; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan.; Department of Neurology, Obihiro Kosei General Hospital, Japan., Matsushima M; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan., Kudo A; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan., Sakushima K; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan., Kanatani Y; Department of Clinical Pharmacology, Faculty of Medicine, Tokai University, Japan., Nishimoto N; Hokkaido University Hospital Clinical Research and Medical Innovation Center, Japan., Sawada J; Department of Cardiology, Nephrology, Pulmonology, and Neurology, Asahikawa Medical University, Japan., Matsuoka T; Department of Neurology, Date Red Cross Hospital, Japan., Hisahara S; Department of Neurology, Sapporo Medical University, Japan., Uesugi H; Aizen Hospital, Japan., Minami N; Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan., Sako K; Department of Neurology, Nakamura Memorial Hospital, Japan., Takei A; Hokkaido Neurological Hospital, Japan., Tamakoshi A; Department of Public Health, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan., Sato N; Hokkaido University Hospital Clinical Research and Medical Innovation Center, Japan., Sasaki H; Hakodate Central General Hospital, Japan., Yabe I; Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan. |
Abstrakt: |
Objective In 2022, Wenning et al. proposed the Movement Disorder Society Criteria (MDS criteria) for the Diagnosis of Multiple System Atrophy (MSA). These criteria were expected to provide useful alternatives to the second consensus statement. We examined trends in these diagnostic criteria. Methods We used patient data registered with the Hokkaido Rare Disease Consortium for Multiple System Atrophy, which has been recruiting patients with MSA through medical facilities in Hokkaido since November 2014. Patients were evaluated according to the MDS criteria based on neurological examinations and imaging findings at three separate times: the first evaluation, the time of enrollment (diagnosis), and the most recent evaluation (final evaluation). Results The MDS criteria were examined in 68 of 244 patients enrolled between November 2014 and July 2022. At the initial evaluation, the classifications were as follows: clinically established (n=27; 39.7%); clinically probable (n=13; 19.1%); possible prodromal (n=12; 17.6%); and negative [did not meet criteria (n=16; 23.5%)]. At the time of diagnosis, the classifications were as follows: clinically established (n=45; 66.2%); clinically probable (n=12; 17.6%); possible prodromal (n=4; 5.9%); and negative (n=7; 10.3%). At the final evaluation, the classifications were as follows: clinically established (n=52; 76.5%); clinically probable (n=9; 13.2%); possible prodromal (n=2; 2.9%); and negative (n=5; 7.4%). Conclusion We were able to clarify the changes in the criteria values and transition of patients due to the clarification of imaging and supportive findings in the MDS criteria. |